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A B S T R A C T   
NRF2 (NFE2L2) is a cytoprotective transcription factor associated with >60 human diseases, adverse drug re-
actions and therapeutic resistance. To provide insight into the complex regulation of NRF2 responses, 1962 
predicted NRF2-partner interactions were systematically tested to generate an experimentally defined high- 
density human NRF2 interactome. Verification and conditional stratification of 46 new NRF2 partners was 
achieved by co-immunoprecipitation and the novel integration of quantitative data from dual luminescence- 
based co-immunoprecipitation (DULIP) assays and live-cell fluorescence cross-correlation spectroscopy (FCCS). 
The functional impact of new partners was then assessed in genetically edited loss-of-function (NRF2  /  ) and 
disease-related gain-of-function (NRF2T80K and KEAP1  /  ) cell-lines. Of the new partners investigated >77% 
(17/22) modified NRF2 responses, including partners that only exhibited effects under disease-related condi-
tions. This experimentally defined binary NRF2 interactome provides a new vision of the complex molecular 
networks that govern the modulation and consequence of NRF2 activity in health and disease.   
1. Introduction 
The human NFE2L2 (NRF2) gene encodes a cap’n’collar (CNC) basic 
leucine zipper (bZIP) transcription factor. In addition to its well estab-
lished role in redox homeostasis [1,2] there is increasing evidence that 
NRF2 has pleotropic effects on many cellular processes, driving 
expression of >240 functionally diverse genes [3]. The fundamental 
importance of the human NRF2 response network is emphasised by its 
association with >60 human diseases [4]. However, despite intense 
research, details of conditional regulation, functional-crosstalk or feed-
back within the human NRF2 network remain incomplete. 
At the protein level, NRF2 is composed of seven conserved NRF2- 
ECH (Neh) domains (Fig. 1A). Neh1 contains the CNC bZIP region, 
which facilitates heterodimerization with sMAF proteins (MAFG, MAFK, 
or MAFF) and binding to antioxidant response element (ARE) motifs in 
the promoter region of NRF2 target genes [5]. In contrast, the Neh2 
domain mediates NRF2 degradation, primarily via the CRL3KEAP1 com-
plex [6,7] but also via CRL4BDCAF11 [8]. The Neh6 domain also harbours 
degrons that facilitate SCFβ  TrCP-mediated degradation [9,10]. Neh3, 4, 
and 5 facilitate interactions with transcriptional co-activators, such as 
chromodomain-helicase DNA binding protein 6 (CHD6) (Neh3 domain), 
CREB binding protein (CBP), and p300 (Neh4 and 5 region) [11–13]. 
Finally, the Neh7 domain mediates an interaction with the nuclear re-
ceptor retinoic X receptor alpha (RXRα), which represses ARE trans-
activation [14]. Given the functional differences between NRF2 
domains, it is important to define where different partners interact, and 
their potential for competitive or conditional binding. 
Under basal conditions NRF2 is sequestered in the cytoplasm 
through a direct interaction with KEAP1. This interaction leads to NRF2 
ubiquitination and proteasomal degradation, ensuring low basal activ-
ity. Upon oxidative or xenobiotic insult, the KEAP1/NRF2 interaction is 
perturbed, preventing NRF2 degradation and allowing nascent NRF2 to 
drive transactivation of ARE-responsive genes, including NQO1, GCLM, 
and HMOX1 [15–19]. However, there is increasing evidence that NRF2 
activity can be modulated by other processes, including 
pro-inflammatory mitogen-activated kinase (MAPK) [20], nuclear factor 
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kappa-B (NF-κB) [21], ER stress [5], and p53 response pathways [22]. In 
this context, it is conceivable that in order to maintain homeostasis, 
NRF2 may have evolved the ability to mediate the dynamic integration 
of responses from multiple stress response pathways. The diverse spec-
trum of NRF2 response genes and predicted interaction partners also 
implies a potential for complex mechanisms of conditional regulation 
and functional crosstalk with other biological processes. 
Although induction of NRF2 counteracts the detrimental effects of 
inflammation [23], cardiovascular disease [24] and DNA damage [25], 
genetic mutations that constitutively enhance NRF2 activity are linked 
to therapeutic resistance and poor prognosis in several forms of cancer 
[26–29]. As such, there is a need to develop new strategies to selectively 
modulate NRF2 responses under different pathological conditions. 
Unfortunately, lack of experimental evidence and systems-level analyses 
impedes mechanistic understanding of how NRF2 responses may be 
modulated, or the effects that changes in NRF2 activity may have on 
other cellular processes. Therefore, a more detailed functionally defined 
map of the human NRF2 interactome is required to inform development 
of improved therapeutic strategies. In addition to the 37 known binary 
human NRF2 interaction partners, a large-scale in silico study provided 
an intriguing insight into the potential complexity and diversity of the 
human NRF2 interactome, and its connectivity to other physiological 
and disease-related processes [30]. As a large proportion of these pu-
tative interactions were untested, we sought to generate a new 
high-density experimentally defined human NRF2 interactome, 
including verification, stratification, and functional analysis of novel 
Fig. 1. Preliminary experimental screens of novel predicted NRF2 interaction partners. (A) Human NFE2L2/NRF2-domain structure and fragments used in 
Y2H matrix screens. (B) Partner/NRF2-domain interaction preferences. (C) NRF2 binary interaction network showing all Y2H positive partners. Outer shell rep-
resents edges re-confirmed in co-immunoprecipitation assays. Transcription factors (TFs) are bordered in red, bZIP TFs in pink, and a kinase in light green. As the 
Neh4 and Neh5 domains tended to auto-activate Y2H reporters we were unable to define partner profiles for most of these regions. Auto-activating clones are shown 
in red. One Neh457 prey clone did not auto-activate and was used in the screen. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the Web version of this article.) 
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partners. To maximise network coverage partner interaction screens 
were initially performed in high-stringency targeted yeast two-hybrid 
assays, which have the ability to detect weak yet functionally verifi-
able interactions [31,32]. In addition to conventional 
co-immunoprecipitation studies, a novel approach of combining 
live-cell fluorescence cross-correlation spectroscopy (FCCS) with 
high-sensitivity dual luminescence-based co-immunoprecipitation 
(DULIP) assays was used to calculate in vivo partner Kd values and 
stratify conditional partner preferences. Finally, a predictive analysis of 
biological function and disease association was performed to provide 
new insight into potential mechanistic links to human disease 
phenotypes. 
2. Results and discussion 
2.1. Experimental screening of predicted human NRF2 binary interaction 
partners 
A speculative binary human NRF2 network was generated by pre-
diction of domain-motif and domain-domain interactions using the 
Eukaryotic Linear Motif (ELM) and PRINCESS PPI-evaluation tools, as 
previously described [30]; with the inclusion of: (i) additional 
mammalian interologs from BioGRID [33,34], (ii) interologs involving 
the C. elegans NRF2 ortholog SKN-1 in Wormbase [35], WormNet [36], 
and the CCSB Worm ORFeome [37], (iii) interologs from the Drosophila 
melanogaster ortholog CncC in Flybase [38] and BioGRID databases, as 
well as (iv) predictions from the Reactome Functional Interactome 
(ReactomeFI) [39]. This resulted in a predicted network containing 187 
potential binary NRF2 interaction partners (Supplementary Table S1); 
including 132 previously predicted NRF2 partners [30], together with 
additional non-mammalian interologs. In total, 133 of these putative 
binary NRF2 partners were cloned into yeast two-hybrid (Y2H) prey 
(pACTBE-B/pACTBD-B) and bait (pGBAE-B/pGBAD-B) expression vec-
tors [40]. Following removal of auto-activating clones, 87 unique bait 
and 124 unique prey clones were generated (Supplementary Table S2). 
To identify NRF2 domain-specific interactions, fragments corresponding 
to individual and combined NRF2 Neh domains were generated, 
alongside full-length NRF2 (Fig. 1A). As constructs containing NRF2 
Neh4 and Neh5 had a propensity to auto-activate it was not possible to 
use most of these clones in Y2H screens. However, one Y2H prey clone 
(Neh457) did not autoactivate and was included in the screen. Using 
all non-auto-activating clones, a total of 1962 binary interactions were 
systematically tested in a series of repeated Y2H matrix screens, 
resulting in the identification of 46 reproducible positive NRF2 partners, 
which show strong evidence of partner/domain specificity (Fig. 1B). 
Significantly, 28% (13/46) of the binary NRF2 partners identified in this 
screen were predicted interologs: seven of which were conserved in 
Drosophila, four in C. elegans, and two in mice, thereby justifying the 
inclusion of more distant orthologs in this study. 
Initially, 43 positive NRF2 partners were expressed as mCherry- 
tagged constructs and tested by co-immunoprecipitation with EGFP- 
tagged NRF2. In total, 62.8% (27/43) of partners were reproducibly 
co-immunoprecipitated with EGFP-tagged NRF2 (Fig. 1C, Supplemen-
tary Fig. S1). As a high number of positive interaction partners were 
identified with the Neh1 or CT domains, it is possible that these proteins 
may act as conditionally competitive partners. Therefore, insight into 
the rank order of partner interaction strength, under basal and dere-
pressed conditions, may aid prediction of conditional changes in partner 
preference. Significantly, a large proportion of new NRF2 partners were 
transcription factors (TFs), eight of which (ATF3, CEBPG, CREBL2, 
CREBZF, DDIT3, FOSB, FOSL2, TEF) belong to the same bZIP family as 
NRF2 (Fig. 1C); thus expanding the spectrum of NRF2 heterodimers, 
which have the potential to modulate ARE transactivation and target 
gene expression profiles. 
Two complementary assays were used to compare the relative 
strength of NRF2-partner interactions. Binding affinities (in vivo Kd 
values) for KEAP1, MAFG and 23 novel NRF2 partners were first 
measured in HEK293T cells using fluorescence cross-correlation spec-
troscopy (FCCS) [41,42] (Fig. 2A). Values ranged over two orders of 
magnitude, with KEAP1 being the strongest binding partner, possessing 
an in vivo Kd of 1148 nM (95% CI, 776–1520 nM). This value is higher 
than the published in vitro Kd surface values of 167 and 580 nM for in-
teractions between the NRF2 Neh2 domain or Neh2 peptide and KEAP1, 
respectively [43,44]. This difference may reflect the effects of 
co-complex or competitive binding events in vivo [42]. A large propor-
tion of the partners, including KEAP1 and MAFG, have in vivo Kd values 
of 1000–10,000 nM, however five NRF2 partners (CEBPG, FOSL2, 
CREBL2, EIF3J, and ELF3) displayed very low binding affinities >10, 
000 nM (Fig. 2A, Supplementary Fig. S2-3). To re-assess these trends, the 
high-sensitivity dual luminescence-based co-immunoprecipitation 
(DULIP) method [45] was used to provide an independent measure of 
the relative strength and range of novel partner interactions. Six known 
binary NRF2 partners (MAFG, MAFK, MAFF, KEAP1, ATF4, and PMF1) 
and five known indirect or co-complex partners (BTRC, FBXW11, 
APEX1, COPS7A, JUN) were also included for comparison. As FCCS Kd 
and DULIP Kd values were highly concordant, all DULIP Kd values were 
scaled to equivalent molar concentrations via linear regression (Y 
0.213*X  2.110, ***p  0.001) (Supplementary Fig. S4A, Supple-
mentary Methods). Scaled DULIP ex vivo Kd values similarly spanned 
two orders of magnitude, with six novel partners (CEBPG, FOSB, ELF3, 
FOSL2, DDIT3, and MAP2K6) exhibiting weak binding to NRF2 (scaled 
DULIP Kd > 9000 nM). Significantly, known NRF2 partners exhibited a 
very similar range of binding affinities, ranging from very strong (KEAP1 
and sMAF proteins) to very weak (PMF1 and APEX1) (Fig. 2B). The 
strong correlation between DULIP and FCCS Kd values are shown in 
Fig. 2C. 
Given the dominance of KEAP1 binding under basal conditions, it is 
likely that other mechanisms of functional modulation will be most 
relevant when KEAP1/NRF2 interactions are genetically or condition-
ally disrupted. Therefore, the conditional hierarchy of NRF2-partners, 
and the potential for competitive dominance by KEAP1 was investi-
gated by performing comparative DULIP assays in both WT and genet-
ically edited KEAP1  /  HEK293T cells. While the majority of interaction 
partners exhibit similar scaled DULIP Kd values in WT and KEAP1
  / 
cells (Supplementary Fig. S4B), 13 partners exhibited a >1.25-fold dif-
ference between scaled DULIP Kd values in WT and KEAP1
  /  cells, with 
seven partners (ARPC2, ELK1, ETV6, CREBZF, ATF4, REL, and EIF3J) 
exhibiting a loss of affinity and six partners (JUN, CEBPG, PMF1, FOSL2, 
FOSB, and BTRC) showing a gain of affinity for NRF2 in KEAP1  /  cells 
(Supplementary Fig. S4C). The resulting hierarchical binary NRF2 
interaction network is shown in Fig. 2D. Considering these results, we 
propose that partners exhibiting lower Kd values in KEAP1
  /  cells may 
be competitively inhibited from binding NRF2 under basal conditions. 
However, these partners could in principle modulate NRF2 responses 
either: in the nuclear compartment where KEAP1 levels are low; in 
several forms of cancer, where NRF2/KEAP1 interactions are genetically 
perturbed; or under conditions of oxidative or xenobiotic stress, when 
KEAP1 mediated degradation of NRF2 is inhibited. It is also important to 
note that the rank order of NRF2 partner binding changes under dere-
pressed (KEAP1  /  ) conditions. This quantitative change in partner 
preference may provide a mechanism by which the extent or nature of 
NRF2 transcriptional responses can be conditionally tuned. In contrast, 
an increase in partner Kd values in KEAP1
  /  cells may suggest that 
under basal conditions, these partners could bind cooperatively with 
NRF2 and KEAP1 in multiprotein complexes. Quantitative data from this 
study also supports the current paradigm in which BTRC primarily 
governs nuclear degradation of NRF2 via CUL1-based proteasomal 
degradation under derepressed rather than basal conditions. 
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2.2. Phosphomimetic mutation of NRF2 Y576 inhibits ARE 
transactivation and alters bZIP binding preferences 
Although the Neh1 domain of NRF2 is known to contain the bZIP 
heterodimerization domain, quantitative DULIP assays show that both 
the Neh1 and Neh3 domains of NRF2 are essential for binding to MAFG 
(Supplementary Fig. S5A). This raises the possibility that changes within 
the Neh3 domain may have broader effects on the binding of other bZIP 
proteins in the neighbouring Neh1 region (Fig. 3A). A preliminary 
mutagenesis study of six predicted NRF2 phosphorylation sites S40, T80, 
S215, S408, T559 & Y576 [46] showed that only the phosphomimetic 
Y576E mutation significantly inhibited ARE transactivation 
(Supplementary Fig. S5B and Fig. 3B). As bZIP proteins are known to 
either facilitate or modulate NRF2 transcription, we performed a series 
of DULIP assays to investigate the effects of the Y576E mutation on bZIP 
protein recruitment. Interestingly, this mutation significantly inhibited 
interactions between NRF2/MAFK and NRF2/MAFF, while binding to 
MAFG was unaffected (Fig. 3C). As eight additional NRF2 bZIP-partners 
were identified in this study, the effects of the Y576E mutation on these 
interactions was also tested. While interactions with CREBZF, ATF3, 
CEBPG, and FOSB all remained unchanged, binding to TEF, CREBL2, 
and DDIT3 were significantly increased by the Y567E mutation 
(Fig. 3D). 
These quantitative results provide the first evidence that the Neh3 
Fig. 2. Quantification of NRF2-partner binding strength. (A) EGFP-NRF2 and 25 mCherry-tagged partners were co-expressed as pairs in HEK293T cells and 
interactions were measured in real time in live cells by fluorescence cross-correlation spectroscopy (FCCS). Binding strength is expressed as FCCS in vivo Kd values. 
Error bars represent 95% confidence intervals of the mean, n  30 single-cell measurements from 3 independent experiments for each combination. Threshold of 
positive binding is indicated by dotted line. (B) RL (Renilla-tagged)-NRF2 and 35 FL (firefly-tagged)-partners were co-expressed as pairs in HEK293T cells and in-
teractions were quantified by DULIP. Binding strength is expressed as scaled DULIP Kd values  SEM, n  9 measurements from 3 independent experiments. (C) 
FCCS Kd values are plotted against scaled DULIP Kd values. Correlation between FCCS Kd and scaled DULIP Kd data is represented by Pearson’s r, *** indicates p 
0.001. (D) Protein interaction network showing 27 NRF2 binary partners quantified by DULIP and/or FCCS. Partners confirmed by CoIP are shaded in red, negative 
partners are shaded blue. Shading intensity represents relative decrease or increase in binding affinity in KEAP1  /  cells. Previously known partners are shaded in 
green. Transcription factors (TFs) are bordered in red, bZIP TFs in purple, a kinase in light green, and ubiquitin-related proteins in dark green. Edges represent binary 
NRF2-partner interactions. The network is visualised using Cytoscape in edge-weighted spring embedded layout. Length of edges are weighted by average normalised 
binding affinity from DULIP and FCCS experiments. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of 
this article.) 
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domain of NRF2 is essential for heterodimerization with sMAF proteins. 
While the Neh3 domain may be required to maintain conformational 
integrity of the Neh1 region, our data indicates a possible new mecha-
nism by which Y576 phosphorylation in Neh3 could change the rank 
order of bZIP partner binding, thereby providing a means by which 
NRF2 activity and target gene expression may be conditionally tuned. 
2.3. Functional effects of new NRF2 partners on ARE transactivation 
Due to the dominant nature of the KEAP1/NRF2 interaction, the 
ability of new NRF2 partners to modulate ARE transactivation was 
analysed under both basal and derepressed conditions, using a series of 
CRISPR/Cas9-edited NRF2 gain-of-function (NRF2T80K and KEAP1  /  ) 
and loss-of-function (NRF2  /  ) cell-lines. Evaluation of NRF2 levels 
following treatment with the NRF2 activator sulforaphane (SFN) or the 
proteasomal inhibitor MG132 confirmed that expression of NRF2 was 
abolished in NRF2  /  cell-lines but enhanced in NRF2T80K/T80K, 
NRF2T80K/- and KEAP1  /  cells (Fig. 4A–B). Interestingly, comparative 
qPCR analysis of several NRF2 target genes under unstimulated condi-
tions revealed differences in expression of HMOX1, FTH1, and AKR1C1, 
but not GCLM or NQO1, between KEAP1 binding-impaired (NRF2T80K) 
and KEAP1  /  cell-lines (Fig. 4C–G). This shows that KEAP1 can influ-
ence ARE transactivation, and by extension NRF2 target gene expres-
sion, by some mechanism that is independent of its ability to bind NRF2. 
As KEAP1 is an E3 substrate adaptor these effects could result from 
changes in the degradation of other target proteins, which directly or 
indirectly affect the nature of NRF2 transcriptional responses. Having 
confirmed the functional phenotypes of each cell-line, ARE-luciferase 
reporter assays were performed to compare changes in ARE trans-
activation in response to ectopic expression of NRF2 interaction partners 
in HEK293T WT, NRF2T80K/T80K, NRF2T80K/-, KEAP1  /  and two 
NRF2  /  cell-lines. In total, the effects of 26 partners were examined in 
each of the six cell-lines. The resulting data was fitted using a linear 
mixed model; with the presumption that the effects of partners depen-
dent on derepression of NRF2 would be significantly enhanced in the 
NRF2T80K and KEAP1  /  cell-lines, while the effects of partners specif-
ically dependent on NRF2 would be dampened in the NRF2  /  cell-lines. 
Nine binary NRF2 partners (MAFK, MAFF, MAFG, ETV4, FOSL2, 
CEBPG, ARPC2, EIF3J, and CREBZF) significantly enhanced ARE- 
luciferase activity in HEK293T WT cells, while six partners (ATF3, 
TBP, NFAT5, TEF, RELA, and ELF3) caused inhibition compared to 
empty vector controls (Fig. 4H). ETV4 and CEBPG both exhibited a 
greater upregulation of NRF2 activity under derepressed conditions 
while TBP and NFAT5 caused greater downregulation in both NRF2T80K 
and KEAP1  /  cells. Significantly, RELA impaired ARE-luciferase 
transactivation in all three derepressed NRF2 cell-lines, demonstrating 
a striking conditional dominance under disease-like conditions. While 
ATF3 downregulated ARE-luciferase transactivation in both WT and 
KEAP1  /  cells, this effect was absent in NRF2T80K cells. This again 
emphasises the functional differences between KEAP1 ablation and 
Fig. 3. Effect of NRF2 Y576 mutations on NRF2-bZIP partner interactions. (A) C-terminal region of NRF2 showing the Y576 phosphorylation site in Neh3 and 
bZIP binding partners. Partner interactions that are inhibited or enhanced by the Y576E phospho-mimetic mutation are shown in blue or red, respectively. (B) 
Relative fold change of ARE-luciferase activity following 24 h transfection of NRF2 WT, Y576E, or Y576F, ***p  0.001; one-way ANOVA with Dunnett’s multiple 
comparison post-hoc test; N  3 independent experiments in triplicates. Change in binding strength of the NRF2 Y576E mutant compared to WT NRF2 for MAFG, 
MAFK and MAFF (C) or other NRF2 bZIP partners (D) in DULIP screens, *p  0.05, **p  0.005; one-sample t-test of log2-transformed corrected normalised 
interaction ratios (cNIR); N  3 independent experiments in triplicates. RL, Renilla-tagged; FL, firefly-tagged. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the Web version of this article.) 
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Fig. 4. Effects of new NRF2 partners on ARE transactivation activity. Western blot images showing NRF2 protein levels in WT or genetically edited HEK293T 
cells in the presence or absence of sulforaphane (SFN) (A) or MG132 (B). Images are representative of three independent experiments. Transcript levels of GCLM (C), 
NQO1 (D), HMOX1 (E), FTH1 (F) and AKR1C1 (G) were evaluated by qPCR analysis to show relative levels of gene expression under untreated basal conditions. 
Statistical difference between ΔCt values was determined using one-way ANOVA with Dunnett’s multiple comparison, ***p  0.001 against WT, p  0.05, p 
0.001 against KEAP1  /  ; N  5 independent experiments. Effects of interaction partners on log2-transformed normalised luciferase ratios are described by a linear 
mixed model fitted by residual maximum likelihood (REML). (H) Fold change in ARE-luciferase activity following 24 h transfection of interaction partner in WT cells. 
Values are expressed as estimates  SE. (I) Fold change in ARE-luciferase perturbation in NRF2  /  -1, NRF2  /  -2, NRF2T80K/T80K, NRF2T80K/  , and KEAP1  /  cells 
compared to WT cells. Only significant effects are displayed. Significance was evaluated using Welch-Satterthwaite t-tests; N  3 independent experiments in 
triplicates. (J) Classification of NRF2 interaction partners based on their effects on ARE transactivation. 
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selective genetic derepression of NRF2. Analysis of ARE perturbation in 
NRF2  /  cell-lines shows that the effects of ATF3, TBP, TEF, and ELF3 
are all NRF2-dependent (Fig. 4I). Interestingly, six partners (KPNA4, 
MAP2K6, TADA2A, KPNA2, DDIT3, and KEAP1) that did not perturb 
ARE-luciferase activity in WT cells, did induce significant changes in 
derepressed (NRF2T80K and/or KEAP1  /  ) cells. Of these, KPNA2, 
KPNA4, MAP2K6, and TADA2A all enhanced ARE-luciferase activity. 
Despite being one of the weakest NRF2 binding partners MAP2K6 dis-
playing a strong dependence on disease-related NRF2 derepression; with 
effects being seen in all three derepressed NRF2 cell-lines. Significantly, 
ectopic expression of KEAP1 increased ARE-luciferase transactivation in 
both T80K cell-lines, confirming that KEAP1 can indirectly enhance ARE 
transactivation, via an NRF2-independent mechanism. These functional 
screens demonstrate that the new high-density binary NRF2 interactome 
contains novel activators and inhibitors of ARE transactivation, as well 
as a subset of partners that specifically exhibit NRF2-dependent effects 
under disease-related conditions (Fig. 4J). Finally, it is important to note 
that several of the partners that modulate ARE-luciferase transactivation 
correspond to very weak NRF2 binding partners. 
2.4. Predictive analysis of the expanded human NRF2 interactome 
Functional annotation of the expanded binary interactome was 
performed using Gene Ontology Biological Processes (GO BP) with 
biological processes being grouped according to functional class, using 
the Cytoscape ClueGO plugin [47] (Fig. 5A). In total, 76 GO BP terms 
(grouped into 18 functional classes) were significantly enriched; 
including four previously identified themes (ER stress, cellular response 
to external stimuli, cellular transcription, and cell cycle/DNA damage 
response) and two additional themes (nuclear import, and cell differ-
entiation/development) identified in this study. Considering novel 
partners that significantly alter ARE transactivation, ATF3 and DDIT3 
(both NRF2 repressors) were over-represented in GO BP terms involved 
in ER stress, thus highlighting a novel intersection between oxidative 
and ER stress responses (Fig. 5A). 
An analysis of disease association was also performed on the new 
expanded human NRF2 interactome. In total 334 gene-disease associa-
tions were identified, including 130 (39.9%) from 22 (51.2%) newly 
identified NRF2 partners (Fig. 5B, Supplementary Table S3). Six of the 
new NRF2 partners associated with known NRF2-disease phenotypes 
(Table 1, Supplementary Fig. S6A), and 13 disease phenotypes involved 
four or more binary NRF2 partners (Table 2). Given the potential for 
functional co-operativity between NRF2 partners, the DisGeNET 
network was merged with a PPI network constructed from five publicly 
available human PPI databases (BioGRID [33,34], IntAct [48], HPRD 
[49], HuRI [50], and InnateDB [51]). Disease-centric sub-networks 
involving two or more NRF2 partners were then extracted, excluding 
partner pairs with known physical association (Supplementary 
Fig. S6B). Interestingly, STAT3 and ATM were jointly associated with 
five different NRF2 disease phenotypes (pancreatic neoplasm, squamous 
cell carcinoma, stomach neoplasms, prostatic neoplasms, and mammary 
neoplasms), suggesting possible mechanistic similarities in the patho-
physiology of these diseases. 
3. Conclusions 
Although NRF2 is known to play a major role in redox homeostasis, 
the complex mechanisms by which NRF2 responses are regulated cannot 
be explained by current knowledge of well characterised pathway 
components. This study represents the first large-scale quantitative 
analysis of the human NRF2 protein interaction network. It was 
designed to provide a broader insight into the diverse range of cellular 
components that interact directly with the different functional domains 
of NRF2. Using a combination of high stringency protein interaction 
assays we identified 46 novel binary NRF2 partners (Fig. 6). Signifi-
cantly, >77% of the novel partners tested were shown to effect NRF2 
driven ARE-transactivation. Quantitative analysis of protein interactions 
enabled the rank ordering and strength of partner interactions to be 
defined, both in vitro and in live cells. These data confirm the dominance 
of KEAP1 and sMAF proteins under basal conditions, but reveal an 
emerging model of regulation in which changes that disrupt binding of 
dominant basal partners (KEAP1 and sMAF proteins) allow weaker 
binding partners to interact with NRF2, thereby facilitating changes in 
transcriptional activity. In addition, we provide the first evidence that 
the NRF2 Neh3 domain is essential for recruitment of MAFG, and 
demonstrate that a phosphomimetic Y576E mutation not only inhibits 
ARE transactivation, but also selectively inhibits interactions with 
MAFK and MAFF, while enhancing interactions with other bZIP part-
ners. Finally, we present quantitative data to show that KEAP1 can in-
fluence ARE transactivation in an NRF2 independent manner. 
These data significantly expand the range of candidate proteins that 
have the potential to modulate NRF2 responses. Together they support 
an emerging paradigm that NRF2 acts as a dynamic sensor to facilitate 
communication and balance between multiple conditional stress- 
responses. This new high-density binary NRF2 interactome provides a 
resource to inform future investigation into the complex conditional 
regulation of NRF2 responses, and the development of better rationally 
designed strategies for therapeutic intervention or drug sensitisation. 
4. Material and methods 
4.1. Lead contact and materials availability 
Further information and requests for resources and reagents should 
be directed to and will be fulfilled by the Lead Contact, Christopher M 
Sanderson (, cmsand@liverpool.ac.uk). 
4.2. Experimental model and subject details 
4.2.1. Cell-lines 
Human embryonic kidney (HEK293T) cells were obtained from 
ATCC. All parent and derived HEK293T cell-lines were cultured in 
DMEM with GlutaMAX supplemented with 10% FBS, 1% NEAA, and 1% 
pencillin/streptomycin (Invitrogen) in a humidified atmosphere of 37 C 
and 5% CO2. 
4.3. Method details 
4.3.1. Generation of bait and prey yeast two-hybrid clones 
Generic primers containing Gateway flanking sequences were 
designed to amplify any ORF from pDONR201/221/223 vectors by 
proof-reading PCR to facilitate in vivo gap repair cloning into Gateway 
compatible BamHI linearised bait (pGBAD/E-B) and prey (pACTBD/E-B) 
Y2H vectors [40]. This approach allowed all clones where possible to be 
expressed as both bait and prey fusions. Gap repair reactions were 
performed as previously described [52]. Y2H assays utilised the bait 
PJ69-4a yeast strain and prey PJ69-4α strain. 
4.3.2. Yeast two-hybrid matrix screens 
NRF2 clones were systematically mated against the array of pre-
dicted interaction partners in both bait/prey orientations where 
possible. The Neh4 and Neh5 domains of NRF2 showed a propensity to 
auto-activate in Y2H assays, however this was not the case for the 
combined Neh457 domains, when expressed as a Y2H prey 
construct. Haploid yeast were initially mated on YPAD media for 24 h 
prior to replication onto SD-Leu/-Trp diploid selection media and grown 
for 48 h. Protein-protein interaction was detected following the repli-
cation of diploid yeast onto the above media also lacking adenine or 
histidine (supplemented with 2.5 mM 3-AT). Activation of reporter 
genes ADE2 and HIS3 and thus growth, indicative of protein-protein 
interaction, was scored over a period of 14 days. Only interactions 
reproducibly observed in two independent assays were scored as 
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Fig. 5. Functional and disease association landscape of NRF2 binary partners. (A) Network showing Gene Ontology Biological Process (GO BP) terms between 
levels 3 and 6 that are significantly enriched in NRF2 binary partners, using a cut-off of Bonferroni step-down p-value  0.05 in a two-sided hypergeometric test using 
the Cytoscape ClueGO plugin. Nodes represent GO BP terms grouped according to the degree of overlap in gene-set using a kappa score of 0.5. Node size is pro-
portional to number of associated genes. Nodes are shaded grey if significantly enriched (>50%) in the previous interactome and red if selectively enriched in the 
new high density NRF2 interactome. Blue nodes represent NRF2 binary partners that either inhibit or activate ARE transactivation. Red edges represent protein-term 
interactions and grey edges represent term-term interactions. (B) Disease-gene association network for NRF2 binary partners using a cut-off  0.2 based on the 
DisGeNET tool. Transcription factors are bordered in red, bZIP TFs in pink, kinases in light green, and ubiquitin-related proteins in dark green. Previously known 
partners are shaded in light blue and novel partners from this study in dark blue. Diseases nodes are shaded green if representing a neoplastic process, yellow if 
representing a mental or behavioural process, red if representing a disease or a syndrome, and pink for other abnormalities. Edges represent gene-disease in-
teractions. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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positive interactions. 
4.3.3. Generation of KEAP1  /  , NRF2  /  , and NRF2T80K HEK293T cell- 
lines 
All cell-lines were generated using CRISPR/Cas9 technology. For 
NRF2  /  and KEAP1  /  , HEK293T cells were seeded in 12-well plates 
(1  105 cells/well) 24 h prior to transfection. Cells were transfected 
with 1 μg LentiCRISPR guideRNA plasmids (NRF2, 50-TTACAACTA-
GATGAAGAGAC-3’; KEAP1, 50-GCCAGATCCCAGGCCTAGCG-30) using 
Lipofectamine-2000 (Life Technologies). After 24 h incubation, the 
medium was changed to include 2 μg/mL puromycin (Sigma) and the 
cells were grown for an additional 48 h before limiting dilution and 
selection of positive clonal populations. For NRF2T80K, HEK293T cells 
were seeded in a 96-well plate (1  103 cells/well) 24 h prior to trans-
fection. Cells were co-transfected with 10 pmol Cas9 RNP (Synthego) 
and 100 pmol HDR template supplied as an ssODN (Sigma; 50-AAGA-
CAAGAACAACTCCAAAAGGAGCAAGAGAAAGCCTTTTTCGCTCAGTT 
ACAACTAGACGAGGAAAAAGGA-
GAATTCCTCCCAATTCAGCCAGCCCAGCACATCCAGTCA-
GAAACCAGTGGATCTGCCAACTACTCC-30) for 48 h prior to limiting 
dilution and selection of positive clonal populations. 
4.3.4. Co-immunoprecipitation 
HEK293T cells were co-transfected with 1 μg each of EGFP-tagged 
NRF2 and mCherry-tagged binary partner vectors for 24 h. Cells were 
lysed in NP-40 lysis buffer (0.5% NP-40 substitute, 25 mM Tris-HCl pH 
7.5, 150 mM NaCl, 2 mM MgCl2, 1 mM EGTA, protease and phosphatase 
inhibitor cocktail), following which clarified protein lysates were incu-
bated with GFP-Trap agarose beads (ChromoTek) for 2 h at 4 C, with 
rotation. Beads were collected by centrifugation and washed thrice in 
NP-40 lysis buffer, then once in IP wash buffer (10 mM Tris pH 7.5, 2 
mM MgCl2). Proteins were eluted directly with NuPAGE LDS Sample 
Buffer (Invitrogen) for 10 min at 80 C before being resolved by SDS- 
PAGE and Western blotting. 
4.3.5. FCCS quantification 
FCCS data collection was performed as previously described [41], 
using a 63x/1.4 Plan-Apochromat objective on a Zeiss LSM 780. Briefly, 
HEK293T cells were seeded overnight in four-compartment glass bottom 
dishes (2.5  104 cells/compartment) and transfected with 25 ng of 
EGFP-tagged NRF2 and mCherry-tagged binary partner for 24 h. EGFP 
fluorescence was excited using a 488 nm Argon laser and emission 
collected between 500 and 530 nm, while mCherry fluorescence was 
excited using a 561 nm DPSS diode and emission collected between 590 
and 640 nm. Data from individual cells were collected via 5  2 s 
measurements either in the cytoplasm or nucleus dependent upon 
partner localisation using 0.15–0.3% laser power to minimise bleaching 
and a suitable count rate of approximately 1 kHz count rate per molecule 
(CPM). The autocorrelation Gauto(τ) and cross-correlation Gcross(τ) 
functions were calculated using the ZEN 2012 software. The calculated 
autocorrelation and cross-correlation values were fitted to a 
two-component diffusion model with or without triplet state correction 
respectively using the Levenberg-Marquardt algorithm in MATLAB 
optimisation toolbox. The in vivo Kd values were obtained from 
nonlinear fitting by plotting the fraction of bound EGFP-tagged and 
mCherry-tagged proteins as a function of free mCherry-tagged or 
EGFP-tagged proteins respectively, and averaging the fitted values. 
4.3.6. DULIP quantification 
DULIP was modified from previously described [45]. Briefly, 
HEK293T cells were transfected for 24 h with 25 ng each of Renilla 
luciferase (RL)-tagged NRF2 and firefly luciferase (FL)-tagged binary 
partner vectors. Following transfection for 24 h, cells were lysed in 
DULIP lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, 
1% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA, 1 mM DTT, pro-
tease and phosphatase inhibitor cocktail) and transferred to 96-well 
plates pre-coated with rabbit IgG (Sigma) in carbonate-bicarbonate 
coating buffer (pH 9.6) and blocked with 1% bovine serum albumin 
for 3 h at 4 C. Firefly and Renilla luminescence were measured 
sequentially using a GloMax Multi-Detection System (Promega). 
4.3.7. ARE-luciferase activity screens 
HEK293T cells were co-transfected for 24 h using 100 ng of 8XARE- 
FL, 5 ng of Renilla luciferase (pRL-SV40), as well as 100 ng of an 
expression vector containing the binary partner in a 96-well plate. Cells 
were lysed in Passive Lysis Buffer (Promega) and transferred to a 96-well 
plate before firefly and Renilla luminescence were measured sequen-
tially on a GloMax Multi-Detection System. Log2-normalised luciferase 
fold change was fitted to a linear mixed model with ‘condition’ and ‘cell- 
line’ as fixed effects and ‘plate’ as a random effect using the ‘nlme’ [53] 
and ‘lmerTest’ [54] R packages. p-values were calculated by Sat-
terthwaite’s method for unequal variance and corrected for multiple 
testing using Bonferroni’s method. 
4.3.8. Network construction 
Protein interaction data was extracted and merged from BioGRID 
Table 1 
Disease phenotypes associated with NRF2.  
Disease UMLS CUI NRF2 binary partners associated 
Squamous Cell Carcinoma C0007137 ATM, CREBBP, CSNK2A1, EP300, 
NCOA3, STAT3 
Non-Small Cell Lung Carcinoma C0007131 ATF3, KDM1A, KEAP1, NCOA3, 
STAT3 
Squamous Cell Carcinoma of 
Oesophagus 
C0279626 CDKN1A, CREBBP, EP300 
Liver Neoplasms C0023903 ATF3, FOSB, STAT3 
Liver Carcinoma C2239176 ATM, IRF2, TRIM24 
Skin Neoplasms C0037286 CSNK2A1 
Diabetic Nephropathy C0011881 RELA 
Pulmonary Fibrosis C0034069 – 
Non-Alcoholic Fatty Liver 
Disease 
C0400966 – 
Hyperglycaemia C0020456 – 
Acute Kidney Injury C2609414 – 
Acute Lung Injury C0242488 – 
Kidney Diseases C0022658 – 
Liver Cirrhosis C0023890 – 
Gastrointestinal Diseases C0017178 – 
*Novel partners are highlighted in bold. 
Table 2 
Disease phenotypes associated with multiple NRF2 binary partners.  
Disease UMLS CUI NRF2 binary partners associated 
Schizophrenia C0036341 ATF4, ATM, CASP3, CREBBP, GRB2, 
GSK3B, KAT8, KPNA3, PRKCA, RELA, 
TBP 
Prostatic Neoplasms C0033578 ATF3, ATM, CDKN1A, CREBBP, ETV1, 
ETV4, GSK3B, STAT3 
Mammary Neoplasms C1458155 ATM, DDIT3, EP300, ETS2, ETV4, 
RELA, STAT3 
Acute Myelocytic 
Leukaemia 
C0023467 CREBBP, EP300, ETV6, GATA1, STAT3 
Squamous Cell Carcinoma C0007137 ATM, CREBBP, CSNK2A1, EP300, 
STAT3 
Stomach Neoplasms C0038356 ATM, CDKN1A, IRF1, STAT3 
Ulcerative Colitis C0009324 ARPC2, CASP3, RELA, STAT3 
Colonic Neoplasms C0009375 CDKN1A, LEF1, RELA, STAT3 
Bipolar Disorder C0005586 ATF4, CREBBP, GSK3B, NCOR2 
Diabetes Mellitus, Non- 
Insulin-Dependent 
C0011860 ATF3, CASP3, RELA, UBE2E2 
Non-Small Cell Lung 
Carcinoma 
C0007131 ATF3, KDM1A, KEAP1, STAT3 
Bladder Neoplasm C0005695 ATM, CDKN1A, CREBBP, EP300 
Intellectual Disability C3714756 CREBBP, CSNK2A1, EP300, ZBTB24 
*Novel partners are highlighted in bold. 
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[33,34], IntAct [48], HuRI [50], HPRD [49], and innateDB [51]. The 
predicted binary NRF2 network was generated as previously described 
[30]. To increase network density we also included: (i) additional 
mammalian interologs from BioGRID [33,34], (ii) interologs involving 
the C. elegans NRF2 ortholog SKN-1 in Wormbase [35], WormNet [36] 
and the CCSB Worm ORFeome [37], (iii) interologs from the Drosophila 
melanogaster ortholog CncC in Flybase [38] and BioGRID databases, as 
well as (iv) predictions from the Reactome Functional Interactome 
(ReactomeFI) [39]. Gene-disease association terms were extracted from 
DisGeNET [4] using a cut-off 0.2. Networks were generated and 
visualised using Cytoscape 3.7.1. 
Data and code availability 
MATLAB custom analysis code is available from the lead contact 
upon reasonable request. NRF2 protein-protein interaction data have 
been submitted to the IMEx (http://www.imexconsortium.org) con-
sortium through IntAct [48] (IMEx ID: IM-27648). 
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